Recent findings of the impact of new RSV prevention products aimed at protecting babies were published in the Morbidity and Mortality Weekly Report, an epidemiological digest prepared by the Centers ...

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

The Kids Research Institute Australia’s latest strategy signals a pivotal shift, not just in what it aims to achieve, but how ...